AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
Nov 16 (Reuters) - AstraZeneca AZN.L said on Monday it has won two US drug approvals, an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder.
The US Food and Drug Administration approved Imfinzi, combined with enfortumab vedotin, a targeted therapy prior to surgery, for muscle-invasive bladder cancer patients who are ineligible for or have refused cisplatin-based chemotherapy
The Imfinzi approval was based on a late-stage trial which showed the regimen cut the risk of cancer recurrence by 49% and the risk of death by 42%
Imfinzi is already approved across more than 50 countries and is indicated for a range of cancers including lung and bladder
The FDA also approved Klygefa, developed by AstraZeneca's rare disease unit Alexion, for adults with generalised myasthenia gravis who carry antibodies that attack proteins on the nerves, disrupting communication with muscles
Klygefa also won approval in the EU for the same indication on Monday, adding to its clearances in Japan and other countries for certain adults with gMG